:::

計畫

負責人

研究重點

計畫主持人

黃棣棟

1.Identification/selection Cell surface targets, Therapeutic targets.
2.Therapeutic efficacy validation in-vitro/in-vivo(mice model) platform.

子計畫二

謝嘉玲

1.Novel drug delivery : P-MSC exosome cargo PEG-SPIO labelling-MSCS
2.Novel therapeutic targeted agents conjugation.

子計畫三

謝立群

彭徐鈞

Radiogenomic study of pediatric emdryonal brain tumor

Radiogenomics validation

1.PEG-SPIO labelling-MSCS conjugated agent distribution
2.Efficacy of treatment in mice model

子計畫四

林于鈴

Therapeutic effect of anti-Met drug(DMGF)Preclinical study

 

研究主題:開發高風險兒童髓母細胞瘤的精準標靶治療策略

研究摘要

  In children, high-risk medulloblastoma (MB) includes metastasis at diagnosis and tumor recurrence during or after radiotherapy treatment and/or cytotoxic chemotherapy. The efficacy of conventional treatment is poor, mortality is high, and causes detrimental influence to neurocognitive function and quality of life in survivors. The current therapy is an unmet need for medical and parent’s expectation. This integrated project consists of three subprojects. We aim at the development of precision targeted therapy for more effective but less traumatic therapy in children suffering from high-risk MB.

                                  

研究成果